logo
919-206-7900
Polarean Imaging plc.'s technology is for research use only

Corporate News

Result of AGM

13 July 2020

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that at the AGM held earlier today, all resolutions were duly passed.

Details of the proxy votes received on each resolution by Polarean’s Registrar are set out below:


Resolution

For

Against

Resolution 1

69,040,651

0

Resolution 2

69,035,550

5,101

Resolution 3

69,040,651

0

Resolution 4

69,040,651

0

Resolution 5

69,040,651

0

Resolution 6

69,040,651

0

Resolution 7

69,010,651

0

Resolution 8

68,885,651

125,000

 

Contacts:

 

Polarean Imaging plc

www.polarean.com / www.polarean-ir.com

Richard Hullihen, Chief Executive Officer

Jonathan Allis, Chairman

Via Walbrook PR

 

 

SP Angel Corporate Finance LLP Nomad and Broker

Tel: +44 (0)20 3470 0470

David Hignell / Soltan Tagiev (Corporate Finance)

 

Vadim Alexandre / Rob Rees (Corporate Broking)

 

 

 

Walbrook PR

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus / Anna Dunphy

Mob: +44 (0)7980 541 893/ +44 (0)7876 741 001

 

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical drug-device combination companies operating in the high-resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarized Xenon gas (129Xe) as an imaging agent to visualize ventilation.129Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung, and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging 129Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimize the imaging of 129Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.